RxDoctor Payments Data

Brady Fickenscher, MD

Family Medicine · York, NENPI 1518302157

Payments from drug & device makers

$1,659in general payments, 2019–2025

Across 97 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$103
  • Amgen$76
  • Merck$50
  • Novo Nordisk$35
  • Lilly USA, LLC$30
  • plus $266 from 15 others

What the payments were for

  • Food & beverage$1,659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,659 in reported general payments places this provider in the 70th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$82,402
Medicare patients
269
Services billed
1,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$69,858
XareltoRivaroxaban53$40,066
FarxigaDapagliflozin Propanediol48$36,940
OzempicSemaglutide23$26,033
JardianceEmpagliflozin11$17,850
MounjaroTirzepatide12$13,233
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,916
Aripiprazole29$11,878
Tresiba Flextouch U-100Insulin Degludec11$10,719
AbrysvoRsv Vacc, Pref A And Pref B/Pf26$8,308
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,292
Breo ElliptaFluticasone/Vilanterol20$8,138
MyrbetriqMirabegron26$5,830
Praluent PenAlirocumab12$5,803
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$5,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$12$45,23161 claims
Johnson & JohnsonXarelto$24$40,06653 claims
Novo NordiskOzempic$35$26,03323 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$22$25,88562 claims
Lilly USA, LLCMounjaro$30$13,23312 claims
Astellas Pharma US IncMyrbetriq$103$5,83026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 981 family medicine providers in Nebraska.

Other family medicine in York

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →